Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 9/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | MDM4 | O15151 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22750970 | 0.90 | MAPT (0.82) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL27376361 | 0.87 | MDM2 (0.81) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL9965576 | 0.87 | P4HB (0.81) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL13836560 | 0.87 | P4HB (0.84) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL12297848 | 0.85 | MAPT (0.84) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL15783250 | 0.85 | MAPT (0.77) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL15783168 | 0.85 | MAPT (1.00) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL15783172 | 0.85 | P4HB (0.81) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL15783140 | 0.85 | MDM2 (0.77) | P4HBMAPTTP53SMN1; SMN2MDM2 | |
| SCHEMBL9962888 | 0.84 | P4HB (0.79) | P4HBMAPTTP53SMN1; SMN2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR (US) | 2019-08-22 | — | — | US | disclosed |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-05-28 | — | — | US | disclosed |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| WO-2011082175-A2 | GLYCOSAMINOGLYCAN INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | P4HB 590/4885MAPT 4328/4885TP53 3840/4885 |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | RAC2, BTN3A1, GDI1 | P4HB 2999/4885MAPT 2064/4885TP53 3978/4885 |
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | P4HB 2999/4885MAPT 2064/4885TP53 3978/4885 |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | P4HB 2999/4885MAPT 2064/4885TP53 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.